Glabridin attenuated the cancer stem cells (CSCs) like properties of breast carcinoma cells, which is likely the major underlying cause of breast cancer metastasis and recurrence, by inhibiting the miR-148a/transforming growth factor-beta (TGF-β) drosophila mothers against decapentaplegic protein 2 (SMAD2) pathway both in vitro and in vivo [104]. This evidence concerns the gene SMAD2 and breast carcinoma.